Decoy Therapeutics Inc (DCOY) FinancialsDCOYDecoy Therapeutics Inc

Evaluating the bottom line, Decoy Therapeutics Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -1055.84%, while the net margin is -1042.84%. These profitability ratios, combined with a Return on Equity (ROE) of -827.77%, provide a clear picture of how effectively DCOY converts its operational activities into shareholder value.

In the context of the broader market, DCOY competes directly with industry leaders such as CHGA and BCAB. With a market capitalization of $2.00M, it holds a significant position in the sector. When comparing efficiency, DCOY's gross margin of 100.00% stands against CHGA's N/A and BCAB's 100.00%. Such benchmarking helps identify whether Decoy Therapeutics Inc is trading at a premium or discount relative to its financial performance.

DCOY has not generated any revenue in recent quarters, with a net income loss of $2,373,800 in Q2 2026. The gross margin is currently at 100% for Q2 2026, but this is due to minimal revenue generation. The company has a forward P/E ratio of 0, indicating no expected earnings growth in the near term.